Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 304753, 13 pages
http://dx.doi.org/10.1155/2015/304753
Research Article

A New Double Stranded RNA Suppresses Bladder Cancer Development by Upregulating p21Waf1/CIP1 Expression

1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jie Fang Avenue, Wuhan, Hubei 430030, China
2Institute of Urology of Hubei Province, No. 1095 Jie Fang Avenue, Wuhan, Hubei 430030, China

Received 3 January 2015; Revised 9 March 2015; Accepted 11 March 2015

Academic Editor: Jiing-Kuan Yee

Copyright © 2015 Chenghe Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. S. J. Yun, S.-K. Moon, and W.-J. Kim, “Investigational cell cycle inhibitors in clinical trials for bladder cancer,” Expert Opinion on Investigational Drugs, vol. 22, no. 3, pp. 369–377, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. N. G. Starostina and E. T. Kipreos, “Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors,” Trends in Cell Biology, vol. 22, no. 1, pp. 33–41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. L. A. Stivala, O. Cazzalini, and E. Prosperi, “The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs,” Current Cancer Drug Targets, vol. 12, no. 2, pp. 85–96, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Wang, D. D. Rao, N. Senzer, and J. Nemunaitis, “RNA interference and cancer therapy,” Pharmaceutical Research, vol. 28, no. 12, pp. 2983–2995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ghildiyal and P. D. Zamore, “Small silencing RNAs: an expanding universe,” Nature Reviews Genetics, vol. 10, no. 2, pp. 94–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. F. Place, L. C. Li, D. Pookot, E. J. Noonan, and R. Dahiya, “MicroRNA-373 induces expression of genes with complementary promoter sequences,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1608–1613, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L.-C. Li, S. T. Okino, H. Zhao et al., “Small dsRNAs induce transcriptional activation in human cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17337–17342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Wang, Z. Chen, Q. Ge et al., “Up-regulation of p21 by miRNAs and its implications in bladder cancer cells,” FEBS Letters, vol. 588, no. 24, pp. 4654–4664, 2014. View at Publisher · View at Google Scholar
  10. M. Miyazaki, M. Sakaguchi, I. Akiyama, Y. Sakaguchi, S. Nagamori, and N.-H. Huh, “Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factor beta 1 in human hepatocellular carcinoma cells,” Cancer Research, vol. 64, no. 12, pp. 4155–4161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Y. Park, G.-Y. Kim, S.-K. Moon, W. J. Kim, Y. H. Yoo, and Y. H. Choi, “Fucoidan inhibits the proliferation of human urinary bladder cancer T24 cells by blocking cell cycle progression and inducing apoptosis,” Molecules, vol. 19, no. 5, pp. 5981–5998, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. R. W. Zhang, Y. L. Wang, J. X. Li, H. L. Jin, S. J. Song, and C. S. Huang, “The chinese herb isolate yuanhuacine (YHL-14) induces G2/M arrest in human cancer cells by up-regulating p21 protein expression through an p53 protein-independent cascade,” The Journal of Biological Chemistry, vol. 289, no. 10, pp. 6394–6403, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Q. Li, J. Li, T. Wen et al., “Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway,” Oncotarget, vol. 5, no. 15, pp. 6387–6403, 2014. View at Google Scholar
  14. T. Sperka, J. Wang, and K. L. Rudolph, “DNA damage checkpoints in stem cells, ageing and cancer,” Nature Reviews Molecular Cell Biology, vol. 13, no. 9, pp. 579–590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Obaya, I. Kotenko, M. D. Cole, and J. M. Sedivy, “The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27Kip1to facilitate the activation of Cdk4/6 and early G1 phase progression,” The Journal of Biological Chemistry, vol. 277, no. 34, pp. 31263–31269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Dai, Y. Liu, J. Liu et al., “A novel CyclinE/CyclinA-CDK inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: implications in cancer therapy,” Cancer Letters, vol. 333, no. 1, pp. 103–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Abbas and A. Dutta, “P21 in cancer: intricate networks and multiple activities,” Nature Reviews Cancer, vol. 9, no. 6, pp. 400–414, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Chen, P. Saha, S. Kornbluth, B. D. Dynlacht, and A. Dutta, “Cyclin-binding motifs are essential for the function of p21CIP1,” Molecular and Cellular Biology, vol. 16, no. 9, pp. 4673–4682, 1996. View at Google Scholar · View at Scopus
  19. Z. Chen, R. F. Place, Z.-J. Jia, D. Pookot, R. Dahiya, and L.-C. Li, “Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells,” Molecular Cancer Therapeutics, vol. 7, no. 3, pp. 698–703, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Yang, X. Y. Zheng, J. Qin et al., “Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells,” Cancer Letters, vol. 265, no. 2, pp. 206–214, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Wang, W. Liu, J. Jin, L. Zhou, L. Liang, and Y. Guo, “M-ds-P21 induces cell apoptosis in bladder cancer T24 cells through P53 independent pathway,” Journal of Cancer Research and Therapeutics, vol. 9, no. 1, pp. 54–59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. Stein, D. A. Ginsberg, G. D. Grossfeld et al., “Effect of p21(WAF1/CIP1) expression on tumor progression in bladder cancer,” Journal of the National Cancer Institute, vol. 90, no. 14, pp. 1072–1079, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. H. M. Behnsawy, H. Miyake, M. A. Abdalla, M. A. Sayed, A. E.-F. I. Ahmed, and M. Fujisawa, “Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection,” Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 5, pp. 495–501, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Kang, G. Yang, R. F. Place et al., “Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth,” Cancer Research, vol. 72, no. 19, pp. 5069–5079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. R. F. Place, J. Wang, E. J. Noonan et al., “Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression,” Molecular Therapy—Nucleic Acids, vol. 1, article e15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl, “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” Nature, vol. 411, no. 6836, pp. 494–498, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Zheng, L. Wang, J. Gan, and H. Zhang, “RNA activation: promise as a new weapon against cancer,” Cancer Letters, vol. 355, no. 1, pp. 18–24, 2014. View at Publisher · View at Google Scholar
  28. V. Huang, J. Zheng, Z. Qi et al., “Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells,” PLoS Genetics, vol. 9, no. 9, Article ID e1003821, 2013. View at Google Scholar
  29. V. Portnoy, V. Huang, R. F. Place, and L.-C. Li, “Small RNA and transcriptional upregulation,” Wiley Interdisciplinary Reviews: RNA, vol. 2, no. 5, pp. 748–760, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Huang, R. F. Place, V. Portnoy et al., “Upregulation of Cyclin B1 by miRNA and its implications in cancer,” Nucleic Acids Research, vol. 40, no. 4, pp. 1695–1707, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. M. T. Y. Lam, W. Li, M. G. Rosenfeld, and C. K. Glass, “Enhancer RNAs and regulated transcriptional programs,” Trends in Biochemical Sciences, vol. 39, no. 4, pp. 170–182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Hah, S. Murakami, A. Nagari, C. G. Danko, and W. Lee Kraus, “Enhancer transcripts mark active estrogen receptor binding sites,” Genome Research, vol. 23, no. 8, pp. 1210–1223, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Nishizawa, T. Okumura, Y. Ikeya, and T. Kimura, “Regulation of inducible gene expression by natural antisense transcripts,” Frontiers in Bioscience, vol. 17, no. 3, pp. 938–958, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Li and R. Ramchandran, “Natural antisense transcript: a concomitant engagement with protein-coding transcript,” Oncotarget, vol. 1, no. 6, pp. 447–452, 2010. View at Google Scholar · View at Scopus
  35. The Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of urothelial bladder carcinoma,” Nature, vol. 507, no. 7492, pp. 315–322, 2014. View at Publisher · View at Google Scholar
  36. X.-R. Wu, “Urothelial tumorigenesis: a tale of divergent pathways,” Nature Reviews Cancer, vol. 5, no. 9, pp. 713–725, 2005. View at Publisher · View at Google Scholar · View at Scopus